Bartosz Chmielowski

Jan 10, 2025 | onclive.com | Bartosz Chmielowski

“The story of oncolytic viruses is not completely new. For years, people knew herpes-based viruses could proliferate in the tumor environment. [Through this], they can destroy a local tumor, which leads to local inflammation, cytokine release, and possible release of tumor antigens.

Aug 17, 2023 | nature.com | Ari Vander Walde |Katie Campbell |Philip O. Scumpia |Alexandra Ikeguchi |Bartosz Chmielowski |Kim Margolin | +3 more

AbstractIn this randomized phase 2 trial, blockade of cytotoxic T-lymphocyte protein 4 (CTLA-4) with continuation of programmed death protein 1 (PD-1) blockade in patients with metastatic melanoma who had received front-line anti-PD-1 or therapy against programmed cell death 1 ligand 1 and whose tumors progressed was tested in comparison with CTLA-4 blockade alone.

Feb 7, 2023 | onclive.com | Bartosz Chmielowski

Bartosz Chmielowski, MD, health sciences clinical professor of medicine, the Division of Hematology-Oncology, Sarcoma and Connective Tissue Medical Oncology, the University of California, Los Angeles (UCLA) Health, discusses the current treatment landscape of metastatic melanoma.

Feb 7, 2023 | onclive.com | Bartosz Chmielowski

Bartosz Chmielowski, MD, health sciences clinical professor of medicine, the Division of Hematology-Oncology, Sarcoma and Connective Tissue Medical Oncology, the University of California, Los Angeles (UCLA) Health, discusses the current treatment landscape of melanoma. The treatment landscape of patients with melanoma has shifted within recent years, according to Chmielowski. This shift can be attributed to many advancements throughout the landscape, such as anti–PD-1-based therapies.

Jan 25, 2023 | onclive.com | Bartosz Chmielowski

Bartosz Chmielowski, MD, health sciences clinical professor of medicine, the Division of Hematology-Oncology, Sarcoma and Connective Tissue Medical Oncology, the University of California, Los Angeles (UCLA) Health, discusses the potential role of vusolimogene oderparepvec (RP1) in the treatment of patients with melanoma who failed prior treatment with an anti–PD-1 therapy.